Literature DB >> 32417911

Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression.

Rosalinde Stal1, Floris van Gaalen1, Alexandre Sepriano1,2, Juergen Braun3, Monique Reijnierse4, Rosaline van den Berg1, Désirée van der Heijde1, Xenofon Baraliakos3.   

Abstract

OBJECTIVES: To evaluate the occurrence and progression of facet joint ankylosis in the whole spine using low-dose CT (ldCT) in radiographic axial spondyloarthritis (r-axSpA) and compare progression of facet joint ankylosis and syndesmophytes.
METHODS: Patients with r-axSpA from the Sensitive Imaging in Ankylosing Spondylitis (SIAS) cohort underwent ldCT at baseline (n = 60) and 2 years (n = 53). Facet joints (right and left, levels C2-S1) were scored as ankylosed, not ankylosed or unable to assess. Joints that were frequently poorly visible (>15% missing), were excluded. Inter-reader reliability on the patient level was assessed with intraclass correlation coefficients (ICCs) and smallest detectable change (SDC). Ankylosis was assessed at joint level and patient level for both timepoints. Syndesmophytes were assessed with CT syndesmophyte score.
RESULTS: Levels C5-T2 were difficult to assess and excluded from all further analyses. Facet joint ICCs were good to excellent for status scores (0.72-0.93) and poor to excellent for progression scores (0.10-0.91). Facet joint ankylosis was detected at every level but most frequently in the thoracic joints. In total, 48% of patients showed 2-year progression. Most progression occurred in the thoracic segment. Using SDCs as cutoff, 18% of patients had progression of facet joint ankylosis only, whereas 20% of patients had progression of syndesmophytes only.
CONCLUSION: This is the first study evaluating facet joints in the whole spine by ldCT in r-axSpA. Facet joint ankylosis was detected most often in the thoracic spine. Assessing facet joints in addition to syndesmophytes detected substantially more patients with damage progression over two years.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Entities:  

Keywords:  ankylosing spondylitis; low-dose computed tomography; outcomes research; spondyloarthritis

Year:  2020        PMID: 32417911     DOI: 10.1093/rheumatology/keaa155

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis.

Authors:  Sungsin Jo; Subin Weon; Bora Nam; Mi-Ae Jang; Hyundeok Kang; Tae-Jong Kim; Ye-Soo Park; Tae-Hwan Kim
Journal:  Arthritis Res Ther       Date:  2021-12-08       Impact factor: 5.156

Review 2.  Future of Low-Dose Computed Tomography and Dual-Energy Computed Tomography in Axial Spondyloarthritis.

Authors:  Torsten Diekhoff; Kay Geert A Hermann; Robert G Lambert
Journal:  Curr Rheumatol Rep       Date:  2022-04-09       Impact factor: 4.686

3.  Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis.

Authors:  Murat Torgutalp; Valeria Rios Rodriguez; Ani Dilbaryan; Fabian Proft; Mikhail Protopopov; Maryna Verba; Judith Rademacher; Hildrun Haibel; Joachim Sieper; Martin Rudwaleit; Denis Poddubnyy
Journal:  Ann Rheum Dis       Date:  2022-06-13       Impact factor: 27.973

4.  CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthritis.

Authors:  Dominik Deppe; Kay-Geert Hermann; Fabian Proft; Denis Poddubnyy; Felix Radny; Mikhail Protopopov; Marcus R Makowski; Torsten Diekhoff
Journal:  RMD Open       Date:  2021-05

5.  Choose wisely: imaging for diagnosis of axial spondyloarthritis.

Authors:  Torsten Diekhoff; Iris Eshed; Felix Radny; Katharina Ziegeler; Fabian Proft; Juliane Greese; Dominik Deppe; Robert Biesen; Kay Geert Hermann; Denis Poddubnyy
Journal:  Ann Rheum Dis       Date:  2021-05-28       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.